Some FéRI research teams joining the COVID19 vaccine race

Some FéRI research teams joining the COVID19 vaccine race

1st July 2020

The Anti-Parasitic BioPharmaceuticals team (BioMAP) of the Joint Research Unit in Infectious Disease and Public Health (UMR ISP) of INRAE ​​and the University of Tours led by Professor Isabelle Dimier-Poisson has just received pleasant news: their NANO-SARS-Cov-2 project has been selected in the Research-Action call for projects (RA-Covid-19) from the National Agency for Research (ANR).

With the company Vaxinano of Professor Didier Betbeder, the BioMAP team has developed in recent years a mucosal subunit vaccine against toxoplasmosis consisting of biocompatible and biodegradable nanoparticles and antigens of the pathogen. As part of the NANO-SARS-Cov-2 project, this vaccine strategy will be adapted to COVID-19. Thus, the candidate vaccine will consist of these same nanoparticles encapsulating the antigenic candidates S and N of the virus or associating the viral VLPs and will be tested soon. After administration by nasal route, researchers will study the humoral and cellular immune response at the level of the mucous and systemic compartments. The Bio3 Institute of Tours and two other research teams are also participating in the project: the BIP team of Antoine Touzé of the UMR ISP 1282 and the AGIR team of François Helle of the UR UPJV 4294 of the University of Picardy Jules Verne.

Link : https://pharma.univ-tours.fr/recherche/accueil-actualites-/vaccin-anti-covid19-a-la-faculte-de-pharmacie-de-tours-l-equipe-biomap-laureate-de-l-anr-ra-covid-19-se-lance-dans-la-course-765051.kjsp